290 related articles for article (PubMed ID: 17928344)
1. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
[TBL] [Abstract][Full Text] [Related]
2. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
3. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
[TBL] [Abstract][Full Text] [Related]
5. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
[TBL] [Abstract][Full Text] [Related]
6. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
7. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
8. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
9. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
[TBL] [Abstract][Full Text] [Related]
12. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
13. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
14. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
16. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
17. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
[TBL] [Abstract][Full Text] [Related]
18. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
[TBL] [Abstract][Full Text] [Related]
19. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
20. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
